secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001628280-24-020010
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology Q1 2024: $67.2M cash, ONSEMBLE data show 50% ORR in bev naïve mCRC
--------------------------------------------------------------------------------

- Cash and equivalents $67.2M as of March 31, 2024; projected runway into Q3 2025.
- Operating expenses $11.1M, down $1.0M YoY; net cash used in ops $7.7M.
- ONSEMBLE trial: bev naïve patients on onvansertib+SoC had 50% ORR vs 0% for SoC alone.
- Initial readout from first-line RAS-mutated mCRC Phase 2 CRDF-004 trial expected 2H 2024.
- Preclinical AACR data showed onvansertib activity in RAS wild-type mCRC, SCLC, and ovarian cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024020010/0001628280-24-020010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024020010/crdf-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-020010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer